TABLE 5.
Plasma fatty acid (FA) profile in paediatric attention-deficit hyperactivity disorder patients in the second phase (time 1 to time 2)
| FA | Group A | Group B |
|---|---|---|
| 14:0 | 0.92±0.13 | 1.00±0.09 |
| 16:0 | 21.74±0.58 | 21.80±0.52 |
| 17:0 | 0.31±0.01 | 0.32±0.01 |
| 18:0 | 7.24±0.23 | 7.45±0.18 |
| 20:0 | 0.26±0.01 | 0.27±0.02 |
| 22:0 | 0.79±0.05 | 0.84±0.06 |
| 24:0 | 0.50±0.05 | 0.51±0.04 |
| 16:1 | 1.25±0.12 | 1.24±0.09 |
| 18:1 (n-7) | 1.36±0.05* | 1.22±0.02 |
| 18:1 (n-9) | 16.41±0.70 | 16.47±0.53 |
| 22:1 (n-9) | 0.43±0.04 | 0.47±0.04 |
| 24:1 (n-9) | 0.97±0.05 | 1.01±0.06 |
| LA; 18:2 (n-6) | 31.80±0.69 | 31.37±0.76 |
| 18:3 (n-6) | 0.25±0.02† | 0.36±0.03 |
| 20:3 (n-6) | 1.16±0.09 | 1.18±0.07 |
| 20:4 (n-6) | 6.08±0.34 | 6.26±0.45 |
| ALA; 18:3 (n-3) | 0.58±0.04 | 0.61±0.03 |
| EPA; 20:5 (n-3) | 2.50±0.30 | 2.33±0.24 |
| DPA; 22:5 (n-3) | 0.74±0.07 | 0.69±0.07 |
| DHA; 22:6 (n-3) | 2.93±0.25 | 2.66±0.22 |
Following the supplementation of group A with n-3 polyunsaturated FA (PUFA) for an additional period of eight weeks (16 weeks in total), while group B received n-3 PUFA instead of placebo for eight weeks, blood was drawn and plasma FA were separated by gas chromatography. FA proportion is expressed as the percentage of the total amount of FA present. FA contributing less than 0.2% of the total have been omitted. Student’s t test (two-tailed) was used to compare differences between means (± SEM).
P<0.02;
P<0.004. ALA Alpha-linolenic acid; DHA Docosahexaenoic acid; DPA Docosapentaenoic; EPA Eicosapentaenoic acid; LA Linoleic acid